Pullulan acetate nanoparticles prepared by solvent diffusion method for epirubicin chemotherapy

Zhang, Huizhu; Gao, Fuping; Liu, Lingrong; Li, Xuemin; Zhou, Zhimin; Yang, Xinling; Zhang, Qiqing

doi:10.1016/j.colsurfb.2008.12.039

Cited by 92 publications

(47 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Poly ( DL -lactide-coglycolide)-grafted pullulan can form self-assembling nanospheres and controll adriamycin release. Pullulan acetate (PA) is the other important hydrophobized pullulan, which can form self-aggregation nanoparticles as well as its modified materialsn (Zhang et al, 2009;Na et al, 2007).…”

Section: Modified Pullulanmentioning

confidence: 99%

“…amount of DCC and DMAP. Pullulan (Mw = 200,000) Acetic anhydride (Na et al, 2007;Zhang et al, 2009) Modification: 2 g of pullulan, suspended in 20ml of formamide, was dissolved by vigorous stirring at 54 •C. To this solution, 6ml pyridine and 15 ml, 10ml or 7.5ml of acetic anhydride were added to change the acetylation degree.…”

Section: Pullulanmentioning

confidence: 99%

“…Also this method was employed to prepare pullulan acetate (PA) nanoparticles. (Zhang et al, 2009) This technique had some advantages compared with other methods. It is a straightforward technique and the particle size increased from 185.7 nm to 423.0 nm with the degree of acetylation increasing from 2.71 to 3.0.…”

Section: Polysaccharides-based Nanoparticles Through Solvent Diffusiomentioning

confidence: 99%

See 2 more Smart Citations

Nanoparticles Based on Modified Polysaccharides

Namazi¹,

Fathi²,

Heydari³

2012

The Delivery of Nanoparticles

View full text Add to dashboard Cite

Section: Modified Pullulanmentioning

confidence: 99%

Section: Pullulanmentioning

confidence: 99%

Section: Polysaccharides-based Nanoparticles Through Solvent Diffusiomentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticles Based on Modified Polysaccharides

Namazi¹,

Fathi²,

Heydari³

2012

The Delivery of Nanoparticles

View full text Add to dashboard Cite

“…Apart from this, dose dependent hematological and cardiological toxicity are other concern (Plosker & Faulds, 1993;Ormrod et al, 1999). Hence, a number of delivery systems like pullulan acetate NPs (Zhang et al, 2009), self-assembled cholesterolconjugated carboxymethyl curdlan NPs (Li et al, 2010), liposomes (Yang et al, 2013), immunoliposome (Mamot et al, 2005) and polymeric micelles (Harada et al, 2011) have been investigated to improve intravenous administration of epirubicin.…”

Section: Introductionmentioning

confidence: 99%

Improved oral efficacy of epirubicin through polymeric nanoparticles: pharmacodynamic and toxicological investigations

et al. 2016

View full text Add to dashboard Cite

Epirubicin (EPI) elicits poor-oral bioavailability hence commercially available as injection for intravenous administration which follows a rapid increase and fast decay in plasma drug concentration often needs a frequent dosing that may lead to serious side effects. Aim of the present study is to develop a nanoparticulate system which could deliver epirubicin effectively via oral administration and could eventually promote new concept ''chemotherapy at home.'' In this perspective, epirubicin loaded Poly-lactide-co-glycolic acid nanoparticles (EPI-NPs) were developed by double emulsion evaporation techniques and evaluated for its safety and efficacy against Ehrlich's Ascites (EAT) induced tumor in balb/c mice. In vivo fate of nanoparticles after oral administration in Albino wistar rats was also studied. EPI-NPs showed marked reduction in tumor size $40% while tumor size was increased 3.55 and 3.28 folds in control as well as in group treated orally with free epirubicin solution (EPI-S), respectively. Furthermore, toxicological evaluation demonstrated insignificant difference in levels of biomarkers including MDA, CAT, SOD, LDH, CK-MB, AST and ALT when EPI-NPs-oral treatment was compared with control group while levels of these biomarkers were found extremely significant in group treated with EPI-S (i.v). and demonstrated increment in LDH (p50.001), CK-MB (p50.001), AST (p50.001), ALT (p50.001) and MDA levels (p50.001) and reduction in SOD (p50.001) and CAT levels (p50.001) thus confirmed better safety profile of EPI-NPs oral than EPI-S i.v. Biodistribution study demonstrated the presence of NPs in different body organs and blood which suggests probability of NPs translocation across intestine thus at the tumor site.

show abstract

“…highly water-soluble, non-toxic, nonmutagenic, edible, lacks immunogenicity, and usefulness as a plasma expander, multiple hydroxyl groups that can readily be modified chemically (Leathers, 2003;Liu et al, 2008;Singh et al, 2008). Many investigations have reported that some amphiphilic pullulan derivatives can form self-aggregated NPs to be used as the carrier for drug delivery (Zhang et al, 2009;Yang et al, 2010;Lee et al, 2012;Yang et al, 2014). Cholesterol-modified pullulan (CHP), as one of amphiphilic pullulan derivatives, can be synthesized using 1,6-hexyldiisocyanate linkages by the reaction between cholesterol and pullulan (Akiyoshi et al, 1993), and its selfaggregated CHP NPs can be used as drug delivery systems (Akiyoshi et al, 1998;Ikuta et al, 2002;Sunamoto et al, 2006;Shimoda et al, 2012) or artificial molecular chaperones (Nomura et al, 2003;Asayama et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

The preliminary evaluation on cholesterol-modified pullulan as a drug nanocarrier

Shen

Yang

2014

Drug Delivery

View full text Add to dashboard Cite

To further develop cholesterol-modified pullulan self-aggregated nanoparticles (CHSPNs) as a drug nanocarrier, CHSP was synthesized and characterized. Its cholesterol degree determined by 1 H NMR was 5.2 cholesterol groups per hundred glucose units. CHSPNs were prepared in aqueous media and characterized by dynamic laser light-scattering (DLS), zeta potential and transmission electron microscopy (TEM). These nanoparticles were almost spherical in shape, and the zeta potentials of CHSPNs were near zero in aqueous media. CHSPNs can be stable at least 2 months with no significant size and zeta potential changes. Single dose toxicity test in mice was investigated for the safety evaluation of CHSPNs as a drug nanocarrier, and the result showed CHSPNs were well tolerated at the dose of 200 mg/kg in mice. Epirubicin (EPI)-loaded CHSPNs (EPI-CHSPNs) were prepared and the in vivo pharmacokinetics and biodistribution were studied. Compared with the EPI solution, EPI-CHSPNs have exhibited higher plasma drug concentration, longer half-life time (t 1/2 ) and the larger area under-the-curve (AUC). Moreover, the drug level of EPI-CHSPNs increased in liver and decreased in heart. The results indicated that CHSPNs were stable, safe and may be a promising drug delivery carrier.

show abstract

Pullulan acetate nanoparticles prepared by solvent diffusion method for epirubicin chemotherapy

Cited by 92 publications

References 37 publications

Nanoparticles Based on Modified Polysaccharides

Nanoparticles Based on Modified Polysaccharides

Improved oral efficacy of epirubicin through polymeric nanoparticles: pharmacodynamic and toxicological investigations

The preliminary evaluation on cholesterol-modified pullulan as a drug nanocarrier

Contact Info

Product

Resources

About